Company Overview and News

60
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates

1h zacks
The biotech industry witnessed a turnaround in the last three months after struggling in early 2018. The industry has risen 10.2% in the past three months compared with an increase of 5.6% registered by the broader S&P 500. The industry had declined 5% in the first three months of 2018.
WFC WFCNP WFC.WS GILD WFC.PRL KERX ICPT WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN ABUS WFC.PRY WFC.PRX WFC.PRW WFC.PRV

21
Rounds Report: Gemphire Enjoyed A Robust Appreciation Backed By Strong Fundamentals

11h seekingalpha
The bioscience market demonstrated a big comeback today following a slumbering Monday. Many equities under our coverage continued to rally and thereby procure more profits for shareholders.
ENTA MDGL GILD GLMD GEMP ICPT IBB XBI

0
Genentech, Regeneron Find Spots in Fortune’s Top 100 Employer List for Millennials

2018-07-18 biospace
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials. The Fortune/ Great Places to Work survey included companies from multiple industries. To be included in the survey, companies needed to have a minimum of 50 millennials on staff. Genentech and Regeneron came in at numbers 91 and 100 respectively in the annual employee survey conducted by Great Places to Work.
GILD

2
Jim Cramer: 3 Biotech Stocks Show Signs They’re Ready to Climb

2018-07-18 biospace
Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.
CELGZ GILD CELG

47
You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18)

2018-07-18 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday, July 17.
GOOS WSM GILD NFLX ILMN W NDAQ VIRT CELG LULU URBN MCD BBBY

7
Rounds Report: Alpine Immune Sciences Broke The Trend In A Down Market

2018-07-18 seekingalpha
The overall bioscience market started off Monday on a pessimistic note. Nevertheless, several equities under our coverage still posted some gains for investors.
FMAGX GILD ESPR KITE IBB XBI ALPN

69
Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

2018-07-17 seekingalpha
Gilead (GILD) has annual revenues in the HIV class of drugs of over $14.2 billion, and only has one phase 3 drug in clinical trials to protect its dominance in this category. GILD’s $14 billion annual income stream could be in jeopardy, because they are literally one drug approval away from an armageddon they admit in their 10-K is coming. A small competitor, Cytodyn Inc. (OTCQB:CYDY), has been struggling for over a decade to get PRO 140 approved as a salvage therapy to drug resistant HIV patients.
CYDY AMGN GILD JNJ GSK KITE PFE GSK PGNX

2
Biotech: Time To Take Profits?

2018-07-17 seekingalpha
We wrote back in April of this year that we believed the biotech (IBB) complex had bottomed. We projected rising prices over the following months (which after a further month of consolidation), and is exactly how things played out. In theory, swing trading is all about buying low and selling high. In practice, as we all know though, it is a far more difficult proposition.
AMGN GILD BIIB

82
My Top 5 Undervalued DGI Stocks

2018-07-17 seekingalpha
On Saturday afternoon I was watching Regis “Rougarou” Prograis fight on ESPN. If you’re a boxing fan, you’ve got to take a look at this heavy fisted southpaw. He’s got the entire city of New Orleans behind him and he brings a ton of energy to the ring. The kid is tenacious and I think he has the mark of a true champion.
IBM BAC GEC GE C GILD CMCSA TWX NFLX CA TWC BAC JNJ AVGO GNE

30
46 Nasdaq 'Safer' Dividend Net Gains Led By Lam, Western, Broadcom, Vodafone, And KLA-Tencor, Per Broker July Targets

2018-07-17 seekingalpha
46 of 52 NASDAQ Index dividends were presumed "safer" because they showed positive one-year returns and free cash flow yields greater than dividend yields as of 7/12/17.
FOX LRCX VOD VOD GILD CMCSA WDC STX PCAR MCHP KLAC VODPF AVGO CSCO SBUX QCOM FOXA PAYX

34
Your 52 Top Yield, Upside, And Net Gain Nasdaq Stocks For July

2018-07-16 seekingalpha
"The Nasdaq-100 Index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization." 52 pay dividends.
LRCX VOD WYNN VOD GILD FAST CMCSA WDC STX PCAR MCHP KLAC VODPF AVGO KHC CSCO SBUX QCOM PAYX

34
Your 52 Top Yield, Upside, & Net Gain NASDAQ Stocks For July

2018-07-16 seekingalpha
"The Nasdaq-100 Index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization." 52 pay dividends.
LRCX VOD WYNN VOD GILD FAST CMCSA WDC STX PCAR MCHP KLAC VODPF AVGO KHC CSCO SBUX QCOM PAYX

97
March To Freedom Fund Mid-Year Review

2018-07-13 seekingalpha
The first half of 2018 is already over, so it is time to look back at how our portfolio performed, the purchases we made and to check our income growth.
SOJA LMT GIS XOM O.PRF TWX OPRF CVS ABT NKE HON AAPL ABBV DIS ABT VTR HON SO GILD O MA TWC RB CMI TGT V AFL PEP JNJ CVX DG MSFT SBUX ABBV QCOM

0
VC Investment More Than Doubles in Q2, Driven by Megadeals

2018-07-13 genengnews
Biopharma venture capital investment more than doubled compared with a year ago, even as the number of deals stayed flat, according to the most recent quarterly PwC/CB Insights MoneyTree™ Report.
GILD

GILD: Gilead Sciences Analysis and Research Report

2018-03-04 - Asif

Overview Gilead Sciences, Inc. (Gilead, we, its or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, the company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. The company seek to add to its existing portfolio of products through its internal discovery and clinical development programs and through product acquisition and in-licensing strategies. 2017 Highlights Over the past year, the company continued to bring best-in-class drugs to market that advance the standard of care by off...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to GILD / Gilead Sciences, Inc. on message board site Silicon Investor.

Gilead Science (GILD) Followers Gilead Sciences (GILD)
Gilead Sciences, INC George Gilder - Forbes ASAP
Powercosm : Gilder ,Huber-Mills , AMSC , IMG ,... CREE ...? Gilder Biotech Report
Gilder/Huber/Mills u0026amp; the emerging Powercosm technologies
CUSIP: 375558103